1-2 of 2
Christopher Stroh
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations

Joachim Albers, Manja Friese-Hamim, Anderson Clark, Oliver Schadt, Gina Walter-Bausch, Christopher Stroh, Andreas Johne, Niki Karachaliou, Andree Blaukat
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (7): 833–843.
https://doi.org/10.1158/1535-7163.MCT-22-0537
Published: 05 July 2023
View article titled, The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring <em>MET</em> Alterations
Open the PDF for The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring <em>MET</em> Alterations in another window
Journal Articles

Targeting the MET Receptor Tyrosine Kinase as a Strategy for Radiosensitization in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

Lluís Nisa, Paola Francica, Roland Giger, Matúš Medo, Olgun Elicin, Manja Friese-Hamim, Claudia Wilm, Christopher Stroh, Beat Bojaxhiu, Aurélie Quintin, Marco D. Caversaccio, Matthias S. Dettmer, Mélanie Buchwalder, Tess M. Brodie, Daniel M. Aebersold, Yitzhak Zimmer, Thomas E. Carey, Michaela Medová
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (2): 614–626.
https://doi.org/10.1158/1535-7163.MCT-18-1274
Published: 06 February 2020
View article titled, Targeting the MET Receptor Tyrosine Kinase as a Strategy for Radiosensitization in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
Open the PDF for Targeting the MET Receptor Tyrosine Kinase as a Strategy for Radiosensitization in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma in another window
Includes: Supplementary data